🇺🇸 melphalan hydrochloride for injection in United States

49 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Thrombotic Microangiopathy — 8 reports (16.33%)
  2. Retinal Toxicity — 6 reports (12.24%)
  3. Thrombocytopenia — 6 reports (12.24%)
  4. Anaemia — 5 reports (10.2%)
  5. Bacterial Infection — 5 reports (10.2%)
  6. Drug Ineffective For Unapproved Indication — 4 reports (8.16%)
  7. Gene Mutation — 4 reports (8.16%)
  8. Plasma Cell Myeloma — 4 reports (8.16%)
  9. Therapeutic Response Delayed — 4 reports (8.16%)
  10. Blood Lactate Dehydrogenase Increased — 3 reports (6.12%)

Source database →

melphalan hydrochloride for injection in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is melphalan hydrochloride for injection approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for melphalan hydrochloride for injection in United States?

Peking University People's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.